Table 2.
Select List of Data Elements
| Patients with Available Values (N) | DVT Cohort | PE Cohort | Other Patients* | Total | |
|---|---|---|---|---|---|
| Patients (%) | 72,107 | 33,150 | 35,745 | 3,212 |
72,107 (100%) |
| Disposition (inpatient vs. outpatient) | 70,122 | 8,228 (25.5%) |
10,872 (31.3%) |
794 (25.4%) |
19,894 (28.4%) |
| Demographics | |||||
| Male (%) | 72,107 | 17,019 (51.3%) |
16,668 (46.6%) |
1,684 (52.4%) |
35,371 (49.1%) |
| Age (years ± SD) | 72,107 | 63.5±18 | 67.3±17 | 63.5±15.4 | 65.4±17.5 |
| Body mass index (kg/m2) | 50,118 | 27.6±5.2 | 28.2±5.7 | 27±5.2‡ | 27.8±5.5 |
| Underlying conditions | |||||
| Chronic lung disease | 72,107 | 2,800 (8.4%) |
5,112 (14.3%) |
326 (10.1%) |
8,238 (11.4%) |
| Chronic heart failure | 72,107 | 1,455 (4.4%) |
3,263 (9.1%) |
137 (4.3%) |
4,855 (6.7%) |
| Diabetes | 45,033 | 2,778 (14.8%) |
3,693 (16%) |
585 (18.7%) |
7,056 (15.7%) |
| Hypertension | 45,263 | 8,117 (43%) |
11,869 (51%) |
1,409 (44.9%) |
21,395 (47.3%) |
| Prior myocardial infarction | 45,002 | 1,224 (6.5%) |
1,918 (8.3%) |
176 (5.7%) |
3,318 (7.4%) |
| Prior ischemic stroke | 44,981 | 1,095 (5.8%) |
1,800 (7.8%) |
170 (5.5%) |
3,065 (6.8%) |
| Recent major bleeding | 72,107 | 678 (2%) |
836 (2.3%) |
125 (3.9%) |
1,639 (2.3%) |
| Anemia | 72,107 | 11,883 (35.8%) |
11,680 (32.7%) |
1,410 (43.9%) |
24,973 (34.6%) |
| Platelet count <150,000 | 71,990 | 885 (2.7%) |
823 (2.3%) |
144 (4.6%) |
1,852 (2.6%) |
| Platelet count >450,000 | 71,990 | 1,113 (3.4%) |
1,264 (3.5%) |
155 (4.9%) |
2,532 (3.5%) |
| Recent Surgery | 72,107 | 3,476 (10.5%) |
4,241 (11.9%) |
316 (9.8%) |
8,033 (11.1%) |
| Recent immobility | 72,107 | 7,530 (22.7%) |
7,642 (21.4%) |
464 (14.4%) |
15,636 (21.7%) |
| Active cancer | 72,107 | 7,655 (23.1%) |
7,974 (22.3%) |
1,612 (50.2%) |
17,241 (23.9%) |
| Prior VTE | 72,107 | 5,336 (16.1%) |
5,258 (14.7%) |
272 (8.5%) |
10,866 (15.1%) |
| Pregnancy/puerperium | 72,107 | 561 (1.7%) |
314 (0.9%) |
31 (1%) |
906 (1.3%) |
| Hormonal use | 72,107 | 1,779 (5.4%) |
1,916 (5.4%) |
158 (4.9%) |
3,853 (5.3%) |
| Initial therapy | |||||
| Low-molecular-weight heparin | 72,107 | 30,634 (92.4%) |
30,138 (84.3%) |
2,504 (78%) |
63,276 (87.8%) |
| Unfractionated heparin | 72,107 | 877 (2.6%) |
3413 (9.5%) |
94 (2.9%) |
4,384 (6.1%) |
| Fondaparinux | 72,107 | 736 (2.2%) |
613 (1.7%) |
92 (2.9%) |
1,441 (2%) |
| NOACs | 20,792 | 579 (7.1%) |
417 (4%) |
35 (1.6%) |
1,031 (5.0%) |
| Thrombolytic therapy | 72,107 | 54 (0.2%) |
882 (2.5%) |
3 (0.1%) |
939 (1.3%) |
| Vena cava filter use | 72,107 | 720 (2.2%) |
1,042 (2.9%) |
80 (2.5%) |
1,842 (2.6%) |
| Clinical Presentation | |||||
| SBP levels <90 mm/Hg | 69,286 | 268 (0.9%) |
1,253 (3.5%) |
37 (1.3%) |
1,558 (2.2%) |
| Syncope | 69,108 | 195 (0.6%) |
5,211Z (15%) |
46 (1.6%) |
5,452 (7.9%) |
| Heart rate >=110 mm/Hg | 67,212 | 1,374 (4.6%) |
7,272 (21%) |
169 (6.1%) |
8,815 (13.1%) |
| Sat O2 levels <90% | 27,097 | 289 (6.9%) |
6,618 (29.6%) |
64 (12%) |
6,971 (25.7%) |
Data include patients enrolled until June 30, 2017.
*
: those with superficial vein thrombosis, splanchnic vein thrombosis (i.e. thrombosis involves thrombosis in the mesenteric, splenic, or portal veins), retinal vein thrombosis, and cerebral vein thrombosis. DVT: deep vein thrombosis, NOAC: Non-vitamin K antagonist oral anticoagulant, PE: pulmonary embolism, VTE: venous thromboembolism.